Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | CX717 in the Treatment of Adult ADHD | ClinicalTrials.gov |
| NCT number | NCT03375021 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 68 participants, actual | ClinicalTrials.gov |
| Lead sponsor | RespireRx | ClinicalTrials.gov |
| Conditions | Attention Deficit Hyperactivity Disorder | ClinicalTrials.gov |
| Interventions | CX717 200 mg, CX717 800 mg, Placebo | ClinicalTrials.gov |
| First posted | 2017-12-15 | ClinicalTrials.gov |
| Last updated | 2017-12-15 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | ADHD-RS | 3 Weeks | Attention-Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) with Prompts The ADHD-RS is an 18-item scale that assesses the severity ADHD symptoms based on the symptom list in the DSM-IV. It is administered by a qualified health care professional. Each item is rated 0 - 3 (0=not present and 3=severe). Thus the scale has a range from 0 to 54. | ClinicalTrials.gov |
| Secondary | ADHD-RS subscales | 3 Weeks | Attention Deficit Hyperactivity Disorder Rating Subscales: hyperactivity consisting of items 1-4, 8-10, 17-18, and inattentiveness consisting of items 5-7 and 11-16. | ClinicalTrials.gov |
| Secondary | CGI-I | 3 Weeks | Clinical Global Impression of Improvement | ClinicalTrials.gov |
| Secondary | HAM-A | 3 Weeks | Hamilton Rating Scale of Anxiety | ClinicalTrials.gov |
| Secondary | HAM-D | 3 Weeks | Hamilton Rating Scale of Depression | ClinicalTrials.gov |
| Secondary | PSQI | 3 Weeks | Pittsburgh Sleep Quality Index | ClinicalTrials.gov |
| Secondary | ESS | 3 Weeks | Eppworth Sleepiness Scale | ClinicalTrials.gov |
| Secondary | ADHD-SRS | 3 Weeks | Attention Deficit Hyperactivity Disorder Self Rating Scale | ClinicalTrials.gov |
| Secondary | SCWT | 3 Weeks | Stroop Color and Word Test | ClinicalTrials.gov |
| Secondary | CTMT | 3 Weeks | Comprehensive Trail Making Test | ClinicalTrials.gov |
| Secondary | CPT | 3 Weeks | Continuous Performance Task | ClinicalTrials.gov |
| Secondary | FBDS | 3 Weeks | Forward and Backward Digit Span | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Continuous Performance Test | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)